Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting and engineering of the fungal and plant genomes, Empyrean is working to enhance and modulate neuroactive compounds produced by these kingdoms. Launched in 2022, the company’s platform is being used […]
EnPlusOne Biosciences aims to bring a versatile, sustainable, and scalable RNA synthesis technology to market to unlock development of new RNA drugs, vaccines, and gene-editing therapies. The company’s advanced-stage technology has more than six years of development at the Wyss Institute at Harvard University, and is co-founded by Dr. George Church of Harvard Medical School. […]
MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporator™ is a non-viral microfluidic platform for highly effective delivery of external cargos such as plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles into primary cells. The Hydroporator™ technology enables high […]